Journal Publications

  1. Thumma MM, Fabbro SK, Mostow EN. Ethical considerations of industry-sponsored residency positions. JAAD 2024; Epub ahead of print.

  2. Rognrud K, Hamburger N, Korman AM, Fabbro SK. Coding Conflicts: Ethical considerations regarding the updated CMS Coding Guidelines. JAAD 2023; Epub ahead of print.

  3. Wyant WA, Fabbro SK, Kaffenberger J, Grant-Kels JM, Korman AM. The ethics of advising dermatology residency applicants in an era of holistic review. Int J Dermatol 2023; S0190-9622(23)01005-8.

  4. Gray A, Fabbro SK, Korman AM. Pretibial Myxedema. Cutis 2023. Epub ahead of print

  5. Fabbro SK, Stoff B. Ethical issues of compounding cantharidin in dermatology. JAAD 2022; S0190-9622(22)02346-5

  6. Korman AM, Fabbro SK. Reply to: “Accessibility of direct-to-consumer dermatology to underserved populations”. JAAD 2022; 86(3); E135.

  7. Korman AM, Fabbro SK. Reply to: “Direct-to-consumer teledermatology platforms may have inherent conflicts of interest”. JAAD 2021; 24:S0190-9622(21)01003-3.

  8. Nasser S, Korman AM, Fabbro SK. Ethics of post-trial access to care in dermatology. JAAD 2021;S0190-9622(21)00980-4.

  9. Fabbro SK, Stoff BK. On the ethical use of biosimilars in dermatology. JAAD 2021;23:S0190-9622(21)00613-7.  

  10. Korman AM, Fabbro SK. Direct-to-consumer pharmaceutical services in dermatology: ethical implications. JAAD 2021; 25:S0190-9622(21)00424-2.

  11. Fabbro SK, Stoff BK. Single blinded peer review: pitfalls with potential bias. JAAD 2020;12:S0190-9622(20)342828-2.

  12. Hwang S, Johnson A, Fabbro S, Hastings J, Haverkos B, Chung C, Porcu P, William B. Topical imiquimod therapy for indolent primary B-cell lymphomas: a single-institution experience. Br J Dermatol 2020; 183(2)::386-387. doi: 10.1111/bjd.18961.

  13. Quaglino P, Maule M, Prince HM, Porcu P, Horowitz S, Duvic M, Talpur R, Vermeer M, Bagot M, Guitart J, Papadavid E, Sanches JA, Hodak E, Sugaya M, Berti E, Ortiz P, Pimpinelli N, Servitje O, Pileri A, Zinzani PL, Estrach T, Knobler R, Stadler R, Fierro M, Alberti S, Amitay I, Antoniou I, Astrua C, Chaganti S, Child F, Combalia A, Fabbro S, et al. Global patterns of care in advanced-stage mycosis fungoides/Sezary Syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. Ann Oncol 2019;30(3): 494.

  14. Quaglino P, Maule M, Prince HM, Porcu P, Horowitz S, Duvic M, Talpur R, Vermeer M, Bagot M, Guitart J, Papadavid E, Sanches JA, Hodak E, Sugaya M, Berti E, Ortiz P, Pimpinelli N, Servitje O, Pileri A, Zinzani PL, Estrach T, Knobler R, Stadler R, Fierro M, Alberti S, Amitay I, Antoniou I, Astrua C, Chaganti S, Child F, Combalia A, Fabbro S, et al. Global patterns of care in advanced-stage mycosis fungoides/Sezary Syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. Ann Oncol 2017;28(10): 2517-2525.

  15. Virmani P, Hwang SH, Hastings JG, Haverkos BM, Kohnken B, Gru AA, Mishra A, Fabbro SK, Horwitz SM, Porcu P. Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why? Expert Rev Hematol 2017;10(2):111-121.

  16. Ferris F, Fabbro S, Gru A, Kaffenberger J. Xanthomatized Neutrophilic Dermatosis in a Patient with Myelodysplastic Syndrome. Am J Dermatopathol 2017;39(5):384-7.

  17. Smith SM, Milam PB, Fabbro SK, Gru AA, Kaffenberger BH. Malignant intertrigo: A subset of toxic erythema of chemotherapy requiring recognition. JAAD Case Reports 2016;2(6), 476.

  18. Kohnken R, Fabbro S, Hastings J, Porcu P, Mishra A. Sézary Syndrome: Clinical and Biological Aspects. Curr Hematol Malig Rep 2016;11(6):468-479.

  19. Kaffenberger JA, Mosser J, Lee G, Pootrakul P, Harfmann K, Fabbro S, Fernandez E, Carr D, Plotner A, Zirwas M, Kaffenberger B. A retrospective analysis comparing the new standardized letter of recommendation in dermatology with the classic narrative letter of recommendation. JClin Aesthet Dermatol 2016;9 (9), 36.

  20. Stoff BK, Scully K, Householder AL, Fabbro SK, Kantor J. The American Academy of Dermatology Ethics Pledge: I will put my patients' welfare above all interests, provide care that adheres to professional standards, provide care for those in need, and foster collegiality through interaction with the medical community. JAAD 2016; 8;75(2):445-8.

  21. Fabbro SK, Stoff BK. The Dermatopathologist's Role in Genetic Testing for Hereditary Cancer Syndromes: Utility versus Patient Liberty. JAAD 2016 6;74(6):1282-5.

  22. Fabbro SK, Smith SM, Dubovsky JA, Gru AA, Jones JA. Panniculitis in Patients Undergoing Treatment With the Bruton Tyrosine Kinase Inhibitor Ibrutinib for Lymphoid Leukemias. JAMA Oncol 2015;8;1(5):684-6.

  23. Fabbro SK, Zirwas MZ. Systemic contact dermatitis to foods: Nickel, BOP and More. Curr Allergy Asthma Rep 2014; 14:463-70.

  24. Kaffenberger BH, Fabbro SK, Harfmann KL. Resident Rounds Part I. Program Spotlight: The Ohio State University. J Drugs Dermatol 2014; 13(8) 752-3.

  25. Fabbro SK, Kaffenberger BH. Resident Rounds Part II. HIV Dermatoses. J Drugs Dermatol 2014; 13(8) 759-61.

  26. Fabbro SK, Kaffenberger BH. Resident Rounds Part III. Plasma cell leukemia with initial cutaneous presentation. J Drugs Dermatol 2014; 13(8) 767-8.

  27. Fabbro SK, Mostow EN, Helms SE, Kasmer R, Helms S, Brodell RT. The pharmacist role in dermatologic care. Curr Pharm Teach Learn 2014; 6(1) 92-105.

  28. Fabbro SK, Aultman JM, Mostow EN. Delusions of parasitosis: Ethical and clinical considerations. JAAD 2013; 69(1) 156-9.

  29. Fabbro SK. On Choosing the “Perfect” Doctor. Virtual Mentor. 2012; 14:928-931. http://virtualmentor.ama-assn.org/2012/12/fred1-1212.html.

  30. Porfeli E, Fabbro SK. Assessing Noncognitive Attributes: The Primary Care Orientation Scale.  Virtual Mentor. 2012; 14:993-997. http://virtualmentor.ama-assn.org/2012/12/stas1-1212.html.